{
    "ticker": "NURO",
    "name": "NeuroBo Pharmaceuticals, Inc.",
    "description": "NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases and related disorders. Founded in 2016, NeuroBo is dedicated to advancing treatments for conditions such as Alzheimer's disease, Parkinson's disease, and chronic pain. The company's lead product candidate, DA-1241, is designed to address the underlying biological mechanisms of neurodegeneration and aims to improve cognitive function and quality of life for patients. NeuroBo employs a unique approach that combines innovative drug development with a commitment to scientific rigor and patient-centric solutions. By collaborating with leading research institutions and leveraging cutting-edge technology, NeuroBo strives to bring transformative therapies to market, enhancing the lives of patients suffering from debilitating neurological conditions. With a pipeline of promising candidates and a team of experienced professionals, NeuroBo is well-positioned to make significant contributions to the field of neurology and improve patient outcomes.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Boston, Massachusetts, USA",
    "founded": "2016",
    "website": "https://www.neurobopharma.com",
    "ceo": "Joseph R. Bae",
    "social_media": {
        "twitter": "https://twitter.com/NeuroBoPharma",
        "linkedin": "https://www.linkedin.com/company/neurobo-pharmaceuticals/"
    },
    "investor_relations": "https://investors.neurobopharma.com",
    "key_executives": [
        {
            "name": "Joseph R. Bae",
            "position": "CEO"
        },
        {
            "name": "Mark H. Hargreaves",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Pharmaceuticals",
            "products": [
                "DA-1241"
            ]
        }
    ],
    "seo": {
        "meta_title": "NeuroBo Pharmaceuticals, Inc. | Innovative Therapies for Neurological Disorders",
        "meta_description": "Explore NeuroBo Pharmaceuticals, Inc., a biotechnology company dedicated to developing novel therapies for neurodegenerative diseases. Discover their innovative product pipeline and commitment to patient care.",
        "keywords": [
            "NeuroBo Pharmaceuticals",
            "Biotechnology",
            "Neurodegenerative Diseases",
            "DA-1241",
            "Alzheimer's Disease",
            "Parkinson's Disease"
        ]
    },
    "faq": [
        {
            "question": "What is NeuroBo Pharmaceuticals focused on?",
            "answer": "NeuroBo Pharmaceuticals focuses on developing therapies for neurodegenerative diseases and related disorders."
        },
        {
            "question": "Who is the CEO of NeuroBo Pharmaceuticals?",
            "answer": "Joseph R. Bae is the CEO of NeuroBo Pharmaceuticals, Inc."
        },
        {
            "question": "Where is NeuroBo Pharmaceuticals headquartered?",
            "answer": "NeuroBo Pharmaceuticals is headquartered in Boston, Massachusetts, USA."
        },
        {
            "question": "What is NeuroBo's lead product candidate?",
            "answer": "NeuroBo's lead product candidate is DA-1241, aimed at treating cognitive impairments associated with neurodegenerative diseases."
        },
        {
            "question": "When was NeuroBo Pharmaceuticals founded?",
            "answer": "NeuroBo Pharmaceuticals was founded in 2016."
        }
    ],
    "competitors": [
        "AVXL",
        "SAVA",
        "PTCT",
        "NTRA"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "BIIB",
        "ILMN"
    ]
}